Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Bought by Millennium Management LLC

Millennium Management LLC raised its stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 96.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,110,298 shares of the company's stock after acquiring an additional 544,881 shares during the period. Millennium Management LLC owned approximately 2.56% of Werewolf Therapeutics worth $2,709,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HOWL. Murchinson Ltd. purchased a new position in shares of Werewolf Therapeutics during the second quarter worth $152,000. Point72 DIFC Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter worth about $34,000. Marshall Wace LLP boosted its holdings in Werewolf Therapeutics by 410.5% during the 2nd quarter. Marshall Wace LLP now owns 134,184 shares of the company's stock valued at $327,000 after acquiring an additional 107,900 shares during the period. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company's stock valued at $417,000 after acquiring an additional 86,800 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Werewolf Therapeutics by 43.9% during the second quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company's stock worth $392,000 after purchasing an additional 48,952 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on HOWL shares. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, July 2nd. JMP Securities reissued a "market outperform" rating and issued a $12.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th.

Werewolf Therapeutics Stock Up 2.5 %

HOWL stock traded up $0.05 during mid-day trading on Wednesday, reaching $2.06. The company had a trading volume of 118,331 shares, compared to its average volume of 242,124. The firm has a fifty day simple moving average of $2.10 and a 200 day simple moving average of $3.38. The company has a debt-to-equity ratio of 0.24, a quick ratio of 12.13 and a current ratio of 12.13. The company has a market capitalization of $89.52 million, a price-to-earnings ratio of -1.89 and a beta of 0.45. Werewolf Therapeutics, Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. The firm had revenue of $1.14 million for the quarter, compared to analysts' expectations of $2.00 million. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.